Arvinas
Approach
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening disease. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. PROTACs application in crop science is being explored through the joint venture, Oerth Bio.